The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients

Abstract

Background Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia. Although potent drugs are emerging, CML and AML may still relapse after the drug treatment is stopped. N6-methyladenosine (m6A) and lncRNAs play certain roles in the occurrence and development of tumors, but m6A-modified LncRNAs in ML remain to be further investigated. Methods In this study, we extracted and analyzed the TCGA gene expression profile of 151 ML patients and the clinical data. On this basis, we then evaluated the immune infiltration capacity of ML and LASSO-penalized Cox analysis was applied to construct the prognostic model based on m6A related lncRNAs to verify the prognostic risk in clinical features of ML. Quantitative reverse transcription PCR was used to detect the expression level of LncRNA in in ML cell lines K562, MOLM13 and acute monocytic leukemia cell line THP-1. Results We found 70 m6A-related lncRNAs that were related to prognosis, and speculated that the content of stromal cells and immune cells would correlate with the survival of patients with ML. Next, Prognostic risk model of m6A-related lncRNAs was validated to have excellent consistency in clinical features of ML. Finally, we verified the expression levels of CRNDE, CHROMR and NARF-IT1 in ML cell lines K562, MOLM13 and acute monocytic leukemia cell line THP-1, which were significant. Conclusions The research provides clues for the prognosis prediction of ML patients by using the m6A-related lncRNAs model we have created, and clarifies the accuracy and authenticity of it.

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

“…There is one azacytidine and B-cell lymphoma/leukemia-2 inhibitor combined with thalidomide for the treatment of clinically advanced MDS, CMML, and AML. The results of the phase II study [ 21 – 23 ] ORR was 63.0%, the overall survival was 28.1 months, and the nonhematotoxicity was grade III or higher 85.0%, indicating that combination therapy is good and that treatment is tolerated. This paper is consistent with the conclusions of relevant foreign studies, and all reflect the combination of azacytidine and B-cell lymphoma/leukemia-2 inhibitors with good efficacy, but the drug toxicity is greater.…”

“…A systematic review and meta-analysis showed that the use of azacytidine and B-cell lymphoma/leukemia-2 inhibitors was associated with an increased risk of decreased neutrophil counts and platelet counts in patients with MDS/AML, and that azacytidine and B-cell lymphoma/leukemia-2 inhibitors did not significantly increase high anemia, leukopenia, or febrile neutrality compared with traditional supportive care risk of agranulocytosis [ 22 ]. In this study, 3 cases of renal function impairment and 7 cases of liver function damage appeared, and foreign studies found that adverse reactions such as elevated serum creatinine occurred during the application of azacytidine and B-cell lymphoma/leukemia-2 inhibitors; so, biochemical indicators such as liver and kidney function should be closely monitored during the chemotherapy process [ 23 ]. Nonhematogenousness is found to cause patients to develop symptoms of the heart system, mainly manifested as left ventricular failure, arrhythmias, hypertension, myocardial infarction, and angina.…”

Antisense lncRNA CHROMR is linked to glioma patient survival

“…CHROMR has also been implicated in elevated risk for stomach adenocarcinoma ( Luo et al, 2022 ), lung adenocarcinoma ( Bai et al, 2022 ), increased resistance to chemotherapy in Lymphoma ( Wang et al, 2022 ), but also in antiviral response to Influenza and COVID-19 infections ( van Solingen et al, 2022 ) and autoimmune disease, such as multiple sclerosis ( Teimuri et al, 2018 ). CHROMR expression is different when comparing lymphoid cancer (high) with myeloid cancer (low) cell lines ( Yang et al, 2022 ). Our results suggest that increased CHROMR expression could be linked to development of malignancy and poorer prognosis for brain glioma patients.…”

RNA Modifications Meet Tumors

“…Similarly, detecting m 6 A modification levels in lncRNA helps evaluate the prognostic level of patients with acute and chronic myelogenous leukemia. 97 , 98 …”